Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir versus placebo in early-onset COVID-19 patients at high risk of severe progression
jRCT2041210004Phase 3Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir with Placebo (2 arms). Primary endpoint: Percentage of patients with severe disease. Started Apr 2021; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2041210004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210004.